Latest efficacy analysis: Taking ixazomib can prevent recurrence for several years

Ixazomib is an oral anticancer drug for multiple myeloma. Each patient's illness, physical condition, treatment methods and other factors will affect the efficacy and maintenance time of ixazomib. According to the prescribing instructions for ixazomib, patients can continue to take the drug if treatment with ixazomib is effective, they can tolerate its side effects, and their condition is under control.

Myeloma can be difficult to deal with, and the time between remission and relapse varies from person to person. Some people have it for a few months, some people have it for a few years. The risk of recurrence is affected by many factors, including individual disease characteristics, clinical manifestations, treatment response, and other potential influencing factors. Ixazomib is usually given as part of maintenance therapy designed to prolong a patient's progression-free survival. Each person's situation is unique, so treatment results and time to relapse will vary. At the same time, patients also need to maintain a healthy lifestyle, such as maintaining good eating habits and exercising appropriately, to promote the absorption and utilization of drugs and improve the therapeutic effect.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.